ISR Articles
-
How Do Experience And Capacity Impact Small Molecule API Outsourcing?
7/16/2019
ISR asked 60 outsourcers of small molecule drug substance manufacturing to select from four different reasons that manufacturing may be split between in-house and external resources.
-
Top Five Satisfaction Drivers For Outsourced Oral Dose Manufacturing
6/14/2019
In Q1, 2019, ISR surveyed 102 sponsors who outsource oral dosage form manufacturing to improve our understanding of what influences customers satisfaction.
-
Top Five Satisfaction Drivers For Outsourced Bioprocessing
6/14/2019
ISR surveyed 100 sponsors who outsource bioprocessing to learn what drives CMO satisfaction. Learn why Quality compliance and Technical capabilities and technical service lead satisfaction drivers.
-
Customer Loyalty In Biologic Drug Product Manufacturing
5/15/2019
ISR surveyed sponsors who outsource drug substance manufacturing for biologic compounds to gain insight into their CMO loyalty. ISR computes customer loyalty as an index that consists of overall satisfaction, willingness to recommend, and likelihood to use the CMO again.
-
Biologic Drug Substance And Drug Product Preferred Provider Use
4/15/2019
ISR data shows the majority of those who outsource biologic drug substance and drug product use a preferred provider approach to outsourcing, and average about four CMOs on their lists.
-
Customer Loyalty In Small Molecule Drug Substance Manufacturing
4/15/2019
In Q4, 2018, ISR surveyed 134 sponsors who outsource drug substance manufacturing for small molecule compounds to gain insight into their CMO loyalty. ISR computes customer loyalty as an index that consists of overall satisfaction, willingness to recommend, and likelihood to use the CMO again.
-
Standing Out In The Crowded Biopharma CDMO Market
3/14/2019
This presentation addresses what motivates drug innovators to outsource, who is involved in service provider selection, and which attributes have the greatest influence on CDMO selection.
-
How Do Experience And Capacity Impact Oral Dose Outsourcing?
2/25/2019
In Q2 2018, ISR asked 44 outsourcers of oral solid dose drug product manufacturing to select from four different reasons that manufacturing may be split between in-house and external resources.
-
Outsourcing Drivers By Company Size
2/25/2019
In Q4 2018, ISR surveyed 121 outsourcers of large molecule drug substance manufacturing to understand their primary reason for working with CMOs for biologic API. The data show respondents from small companies, with an annual R&D spend under $1B, are more likely to use CMOs for all of their manufacturing needs than respondents from large pharma companies (61% vs 24%).
-
Outsourcing Impact Of Focus On Innovative Treatment
11/15/2018
In Q4, 2017, ISR asked a follow-up question to respondents who agreed that their company’s focus on developing new innovative treatments will impact its outsourcing practices.